AC Search
Document Navigator

Autosomal Dominant Polycystic Kidney Disease

Variant: 1   Adult. Suspected autosomal dominant polycystic kidney disease. Positive family history. Initial imaging.
Procedure Appropriateness Category Relative Radiation Level
US kidneys retroperitoneal Usually Appropriate O
MRI abdomen without IV contrast Usually Appropriate O
MRI abdomen without and with IV contrast May Be Appropriate (Disagreement) O
CT abdomen with IV contrast May Be Appropriate ☢☢☢
CT abdomen without IV contrast May Be Appropriate ☢☢☢
CT abdomen and pelvis with IV contrast Usually Not Appropriate ☢☢☢
CT abdomen and pelvis without IV contrast Usually Not Appropriate ☢☢☢
CT abdomen and pelvis without and with IV contrast Usually Not Appropriate ☢☢☢☢
CT abdomen without and with IV contrast Usually Not Appropriate ☢☢☢☢
WBC scan abdomen and pelvis Usually Not Appropriate ☢☢☢☢

Variant: 2   Adult. Known autosomal dominant polycystic kidney disease. Surveillance of total kidney volume.
Procedure Appropriateness Category Relative Radiation Level
MRI abdomen without IV contrast Usually Appropriate O
MRI abdomen without and with IV contrast May Be Appropriate (Disagreement) O
CT abdomen without IV contrast May Be Appropriate ☢☢☢
US kidneys retroperitoneal Usually Not Appropriate O
CT abdomen and pelvis with IV contrast Usually Not Appropriate ☢☢☢
CT abdomen and pelvis without IV contrast Usually Not Appropriate ☢☢☢
CT abdomen with IV contrast Usually Not Appropriate ☢☢☢
CT abdomen and pelvis without and with IV contrast Usually Not Appropriate ☢☢☢☢
CT abdomen without and with IV contrast Usually Not Appropriate ☢☢☢☢
WBC scan abdomen and pelvis Usually Not Appropriate ☢☢☢☢

Variant: 3   Adult. Known autosomal dominant polycystic kidney disease. Suspected complication. Normal kidney function. Initial imaging.
Procedure Appropriateness Category Relative Radiation Level
MRI abdomen without and with IV contrast Usually Appropriate O
CT abdomen and pelvis with IV contrast Usually Appropriate ☢☢☢
MRI abdomen without IV contrast May Be Appropriate (Disagreement) O
CT abdomen and pelvis without IV contrast May Be Appropriate (Disagreement) ☢☢☢
CT abdomen with IV contrast May Be Appropriate (Disagreement) ☢☢☢
CT abdomen without IV contrast May Be Appropriate ☢☢☢
US kidneys retroperitoneal Usually Not Appropriate O
WBC scan with SPECT or SPECT/CT abdomen and pelvis Usually Not Appropriate ☢☢☢
CT abdomen and pelvis without and with IV contrast Usually Not Appropriate ☢☢☢☢
CT abdomen without and with IV contrast Usually Not Appropriate ☢☢☢☢
FDG-PET/CT skull base to mid-thigh Usually Not Appropriate ☢☢☢☢
Gallium scan whole body Usually Not Appropriate ☢☢☢☢

Variant: 4   Adult. Known autosomal dominant polycystic kidney disease. Suspected complications. Reduced kidney function. Initial imaging.
Procedure Appropriateness Category Relative Radiation Level
MRI abdomen without and with IV contrast Usually Appropriate O
MRI abdomen without IV contrast May Be Appropriate O
CT abdomen and pelvis with IV contrast May Be Appropriate ☢☢☢
CT abdomen and pelvis without IV contrast May Be Appropriate (Disagreement) ☢☢☢
US kidneys retroperitoneal Usually Not Appropriate O
CT abdomen with IV contrast Usually Not Appropriate ☢☢☢
CT abdomen without IV contrast Usually Not Appropriate ☢☢☢
WBC scan with SPECT or SPECT/CT abdomen and pelvis Usually Not Appropriate ☢☢☢
CT abdomen and pelvis without and with IV contrast Usually Not Appropriate ☢☢☢☢
CT abdomen without and with IV contrast Usually Not Appropriate ☢☢☢☢
FDG-PET/CT skull base to mid-thigh Usually Not Appropriate ☢☢☢☢
Gallium scan whole body Usually Not Appropriate ☢☢☢☢

Panel Members
Melanie P. Caserta, MDa, Andrei S. Purysko, MDb, Tara M. Catanzano, BCh, MBc, Silvia D. Chang, MDd, Alberto Diaz De Leon, MDe, David S. Goldfarb, MDf, Mary S. Hedges, MDg, Susie Q. Lew, MDh, Refky Nicola, DO, MSci, Venkateswar R. Surabhi, MDj, Myles T. Taffel, MDk, Gaurav Khatri, MDl
Summary of Literature Review
Introduction/Background
Initial Imaging Definition

Initial imaging is defined as imaging at the beginning of the care episode for the medical condition defined by the variant. More than one procedure can be considered usually appropriate in the initial imaging evaluation when:

  • There are procedures that are equivalent alternatives (ie, only one procedure will be ordered to provide the clinical information to effectively manage the patient’s care)

OR

  • There are complementary procedures (ie, more than one procedure is ordered as a set or simultaneously wherein each procedure provides unique clinical information to effectively manage the patient’s care).
Discussion of Procedures by Variant
Variant 1:Adult. Suspected autosomal dominant polycystic kidney disease. Positive family history. Initial imaging.
Variant 1:Adult. Suspected autosomal dominant polycystic kidney disease. Positive family history. Initial imaging.
A. CT abdomen and pelvis with IV contrast
Variant 1:Adult. Suspected autosomal dominant polycystic kidney disease. Positive family history. Initial imaging.
B. CT abdomen and pelvis without and with IV contrast
Variant 1:Adult. Suspected autosomal dominant polycystic kidney disease. Positive family history. Initial imaging.
C. CT abdomen and pelvis without IV contrast
Variant 1:Adult. Suspected autosomal dominant polycystic kidney disease. Positive family history. Initial imaging.
D. CT abdomen with IV contrast
Variant 1:Adult. Suspected autosomal dominant polycystic kidney disease. Positive family history. Initial imaging.
E. CT abdomen without and with IV contrast
Variant 1:Adult. Suspected autosomal dominant polycystic kidney disease. Positive family history. Initial imaging.
F. CT abdomen without IV contrast
Variant 1:Adult. Suspected autosomal dominant polycystic kidney disease. Positive family history. Initial imaging.
G. MRI abdomen without and with IV contrast
Variant 1:Adult. Suspected autosomal dominant polycystic kidney disease. Positive family history. Initial imaging.
H. MRI abdomen without IV contrast
Variant 1:Adult. Suspected autosomal dominant polycystic kidney disease. Positive family history. Initial imaging.
I. US kidneys retroperitoneal
Variant 1:Adult. Suspected autosomal dominant polycystic kidney disease. Positive family history. Initial imaging.
J. WBC scan abdomen and pelvis
Variant 2:Adult. Known autosomal dominant polycystic kidney disease. Surveillance of total kidney volume.
Variant 2:Adult. Known autosomal dominant polycystic kidney disease. Surveillance of total kidney volume.
A. CT abdomen and pelvis with IV contrast
Variant 2:Adult. Known autosomal dominant polycystic kidney disease. Surveillance of total kidney volume.
B. CT abdomen and pelvis without and with IV contrast
Variant 2:Adult. Known autosomal dominant polycystic kidney disease. Surveillance of total kidney volume.
C. CT abdomen and pelvis without IV contrast
Variant 2:Adult. Known autosomal dominant polycystic kidney disease. Surveillance of total kidney volume.
D. CT abdomen with IV contrast
Variant 2:Adult. Known autosomal dominant polycystic kidney disease. Surveillance of total kidney volume.
E. CT abdomen without and with IV contrast
Variant 2:Adult. Known autosomal dominant polycystic kidney disease. Surveillance of total kidney volume.
F. CT abdomen without IV contrast
Variant 2:Adult. Known autosomal dominant polycystic kidney disease. Surveillance of total kidney volume.
G. MRI abdomen without and with IV contrast
Variant 2:Adult. Known autosomal dominant polycystic kidney disease. Surveillance of total kidney volume.
H. MRI abdomen without IV contrast
Variant 2:Adult. Known autosomal dominant polycystic kidney disease. Surveillance of total kidney volume.
I. US kidneys retroperitoneal
Variant 2:Adult. Known autosomal dominant polycystic kidney disease. Surveillance of total kidney volume.
J. WBC scan abdomen and pelvis
Variant 3:Adult. Known autosomal dominant polycystic kidney disease. Suspected complication. Normal kidney function. Initial imaging.
Variant 3:Adult. Known autosomal dominant polycystic kidney disease. Suspected complication. Normal kidney function. Initial imaging.
A. CT abdomen and pelvis with IV contrast
Variant 3:Adult. Known autosomal dominant polycystic kidney disease. Suspected complication. Normal kidney function. Initial imaging.
B. CT abdomen and pelvis without and with IV contrast
Variant 3:Adult. Known autosomal dominant polycystic kidney disease. Suspected complication. Normal kidney function. Initial imaging.
C. CT abdomen and pelvis without IV contrast
Variant 3:Adult. Known autosomal dominant polycystic kidney disease. Suspected complication. Normal kidney function. Initial imaging.
D. CT abdomen with IV contrast
Variant 3:Adult. Known autosomal dominant polycystic kidney disease. Suspected complication. Normal kidney function. Initial imaging.
E. CT abdomen without and with IV contrast
Variant 3:Adult. Known autosomal dominant polycystic kidney disease. Suspected complication. Normal kidney function. Initial imaging.
F. CT abdomen without IV contrast
Variant 3:Adult. Known autosomal dominant polycystic kidney disease. Suspected complication. Normal kidney function. Initial imaging.
G. FDG-PET/CT skull base to mid-thigh
Variant 3:Adult. Known autosomal dominant polycystic kidney disease. Suspected complication. Normal kidney function. Initial imaging.
H. Gallium scan whole body
Variant 3:Adult. Known autosomal dominant polycystic kidney disease. Suspected complication. Normal kidney function. Initial imaging.
I. MRI abdomen without and with IV contrast
Variant 3:Adult. Known autosomal dominant polycystic kidney disease. Suspected complication. Normal kidney function. Initial imaging.
J. MRI abdomen without IV contrast
Variant 3:Adult. Known autosomal dominant polycystic kidney disease. Suspected complication. Normal kidney function. Initial imaging.
K. US kidneys retroperitoneal
Variant 3:Adult. Known autosomal dominant polycystic kidney disease. Suspected complication. Normal kidney function. Initial imaging.
L. WBC scan with SPECT or SPECT/CT abdomen and pelvis
Variant 4:Adult. Known autosomal dominant polycystic kidney disease. Suspected complications. Reduced kidney function. Initial imaging.
Variant 4:Adult. Known autosomal dominant polycystic kidney disease. Suspected complications. Reduced kidney function. Initial imaging.
A. CT abdomen and pelvis with IV contrast
Variant 4:Adult. Known autosomal dominant polycystic kidney disease. Suspected complications. Reduced kidney function. Initial imaging.
B. CT abdomen and pelvis without and with IV contrast
Variant 4:Adult. Known autosomal dominant polycystic kidney disease. Suspected complications. Reduced kidney function. Initial imaging.
C. CT abdomen and pelvis without IV contrast
Variant 4:Adult. Known autosomal dominant polycystic kidney disease. Suspected complications. Reduced kidney function. Initial imaging.
D. CT abdomen with IV contrast
Variant 4:Adult. Known autosomal dominant polycystic kidney disease. Suspected complications. Reduced kidney function. Initial imaging.
E. CT abdomen without and with IV contrast
Variant 4:Adult. Known autosomal dominant polycystic kidney disease. Suspected complications. Reduced kidney function. Initial imaging.
F. CT abdomen without IV contrast
Variant 4:Adult. Known autosomal dominant polycystic kidney disease. Suspected complications. Reduced kidney function. Initial imaging.
G. FDG-PET/CT skull base to mid-thigh
Variant 4:Adult. Known autosomal dominant polycystic kidney disease. Suspected complications. Reduced kidney function. Initial imaging.
H. Gallium scan whole body
Variant 4:Adult. Known autosomal dominant polycystic kidney disease. Suspected complications. Reduced kidney function. Initial imaging.
I. MRI abdomen without and with IV contrast
Variant 4:Adult. Known autosomal dominant polycystic kidney disease. Suspected complications. Reduced kidney function. Initial imaging.
J. MRI abdomen without IV contrast
Variant 4:Adult. Known autosomal dominant polycystic kidney disease. Suspected complications. Reduced kidney function. Initial imaging.
K. US kidneys retroperitoneal
Variant 4:Adult. Known autosomal dominant polycystic kidney disease. Suspected complications. Reduced kidney function. Initial imaging.
L. WBC scan with SPECT or SPECT/CT abdomen and pelvis
Summary of Highlights
Supporting Documents

The evidence table, literature search, and appendix for this topic are available at https://acsearch.acr.org/list. The appendix includes the strength of evidence assessment and the final rating round tabulations for each recommendation.

For additional information on the Appropriateness Criteria methodology and other supporting documents, please go to the ACR website at https://www.acr.org/Clinical-Resources/Clinical-Tools-and-Reference/Appropriateness-Criteria.

Gender Equality and Inclusivity Clause

The ACR acknowledges the limitations in applying inclusive language when citing research studies that predates the use of the current understanding of language inclusive of diversity in sex, intersex, gender, and gender-diverse people. The data variables regarding sex and gender used in the cited literature will not be changed. However, this guideline will use the terminology and definitions as proposed by the National Institutes of Health.

Appropriateness Category Names and Definitions

Appropriateness Category Name

Appropriateness Rating

Appropriateness Category Definition

Usually Appropriate

7, 8, or 9

The imaging procedure or treatment is indicated in the specified clinical scenarios at a favorable risk-benefit ratio for patients.

May Be Appropriate

4, 5, or 6

The imaging procedure or treatment may be indicated in the specified clinical scenarios as an alternative to imaging procedures or treatments with a more favorable risk-benefit ratio, or the risk-benefit ratio for patients is equivocal.

May Be Appropriate (Disagreement)

5

The individual ratings are too dispersed from the panel median. The different label provides transparency regarding the panel’s recommendation. “May be appropriate” is the rating category and a rating of 5 is assigned.

Usually Not Appropriate

1, 2, or 3

The imaging procedure or treatment is unlikely to be indicated in the specified clinical scenarios, or the risk-benefit ratio for patients is likely to be unfavorable.
Relative Radiation Level Information

Potential adverse health effects associated with radiation exposure are an important factor to consider when selecting the appropriate imaging procedure. Because there is a wide range of radiation exposures associated with different diagnostic procedures, a relative radiation level (RRL) indication has been included for each imaging examination. The RRLs are based on effective dose, which is a radiation dose quantity that is used to estimate population total radiation risk associated with an imaging procedure. Patients in the pediatric age group are at inherently higher risk from exposure, because of both organ sensitivity and longer life expectancy (relevant to the long latency that appears to accompany radiation exposure). For these reasons, the RRL dose estimate ranges for pediatric examinations are lower as compared with those specified for adults (see Table below). Additional information regarding radiation dose assessment for imaging examinations can be found in the ACR Appropriateness Criteria® Radiation Dose Assessment Introduction document.

Relative Radiation Level Designations

Relative Radiation Level*

Adult Effective Dose Estimate Range

Pediatric Effective Dose Estimate Range

O

0 mSv

 0 mSv

☢

<0.1 mSv

<0.03 mSv

☢☢

0.1-1 mSv

0.03-0.3 mSv

☢☢☢

1-10 mSv

0.3-3 mSv

☢☢☢☢

10-30 mSv

3-10 mSv

☢☢☢☢☢

30-100 mSv

10-30 mSv

*RRL assignments for some of the examinations cannot be made, because the actual patient doses in these procedures vary as a function of a number of factors (e.g., region of the body exposed to ionizing radiation, the imaging guidance that is used). The RRLs for these examinations are designated as “Varies.”
References
1. Cornec-Le Gall E, Alam A, Perrone RD. Autosomal dominant polycystic kidney disease. [Review]. Lancet. 393(10174):919-935, 2019 03 02.Lancet. 393(10174):919-935, 2019 03 02.
2. Caroli A, Kline TL. Abdominal Imaging in ADPKD: Beyond Total Kidney Volume. J Clin Med. 2023 Aug 05;12(15):5133.
3. Odedra D, Sabongui S, Khalili K, Schieda N, Pei Y, Krishna S. Autosomal Dominant Polycystic Kidney Disease: Role of Imaging in Diagnosis and Management. Radiographics. 2023 Jan;43(1):e220126.
4. Chapman AB, Bost JE, Torres VE, et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2012 Mar;7(3):479-86.
5. Smith AD, Nikolaidis P, Khatri G, et al. ACR Appropriateness Criteria® Acute Pyelonephritis: 2022 Update. J Am Coll Radiol 2022;19:S224-S39.
6. Gupta RT, Kalisz K, Khatri G, et al. ACR Appropriateness Criteria® Acute Onset Flank Pain-Suspicion of Stone Disease (Urolithiasis). J Am Coll Radiol 2023;20:S315-S28.
7. Wang ZJ, Nikolaidis P, Khatri G, et al. ACR Appropriateness Criteria® Indeterminate Renal Mass. J Am Coll Radiol 2020;17:S415-S28.
8. Pei Y, Obaji J, Dupuis A, et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol. 2009 Jan;20(1):205-12.
9. Mai J, Lee VW, Lopez-Vargas P, Vladica P. KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Imaging Approaches for Diagnosis. Semin Nephrol. 2015 Nov;35(6):S0270-9295(15)00170-9.
10. Ars E, Bernis C, Fraga G, et al. Consensus document on autosomal dominant polycystic kindey disease from the Spanish Working Group on Inherited Kindey Diseases. Review 2020. Nefrologia (Engl Ed). 42(4):367-389, 2022 Jul-Aug.
11. Torres VE, Ahn C, Barten TRM, et al. KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary. Kidney Int. 2025 Feb;107(2):S0085-2538(24)00481-2.
12. Pei Y, Hwang YH, Conklin J, et al. Imaging-based diagnosis of autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2015 Mar;26(3):746-53.
13. Pei Y, Watnick T. Diagnosis and screening of autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis. 2010 Mar;17(2):140-52.
14. Chebib FT, Hanna C, Harris PC, Torres VE, Dahl NK. Autosomal Dominant Polycystic Kidney Disease: A Review. JAMA. 2025 May 20;333(19):1708-1719.
15. Alam A, Dahl NK, Lipschutz JH, et al. Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease: A Biomarker of Disease Progression and Therapeutic Efficacy. Am J Kidney Dis. 2015 Oct;66(4):S0272-6386(15)00524-7.
16. Sharma K, Rupprecht C, Caroli A, et al. Automatic Segmentation of Kidneys using Deep Learning for Total Kidney Volume Quantification in Autosomal Dominant Polycystic Kidney Disease. Sci Rep. 2017 May 17;7(1):2049.
17. Kline TL, Edwards ME, Korfiatis P, Akkus Z, Torres VE, Erickson BJ. Semiautomated Segmentation of Polycystic Kidneys in T2-Weighted MR Images. AJR Am J Roentgenol. 207(3):605-13, 2016 Sep.
18. Chapman AB, Guay-Woodford LM, Grantham JJ, et al. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int. 2003 Sep;64(3):1035-45.
19. Irazabal MV, Rangel LJ, Bergstralh EJ, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 26(1):160-72, 2015 Jan.
20. Bevilacqua MU, Hague CJ, Romann A, et al. CT of Kidney Volume in Autosomal Dominant Polycystic Kidney Disease: Accuracy, Reproducibility, and Radiation Dose. Radiology. 2019 Jun;291(3):660-667.
21. Gundogdu E, Cihan C, Yazici C. Total kidney volume in autosomal dominant polycystic kidney disease: intraobserver and interobserver agreement of two methods with MRI. TURK. J. MED. SCI.. 54(3):537-544, 2024.
22. Kline TL, Korfiatis P, Edwards ME, et al. Performance of an Artificial Multi-observer Deep Neural Network for Fully Automated Segmentation of Polycystic Kidneys. J Digit Imaging. 30(4):442-448, 2017 Aug.
23. Simms RJ, Doshi T, Metherall P, et al. A rapid high-performance semi-automated tool to measure total kidney volume from MRI in autosomal dominant polycystic kidney disease. Eur Radiol. 29(8):4188-4197, 2019 Aug.
24. van Gastel MDA, Edwards ME, Torres VE, Erickson BJ, Gansevoort RT, Kline TL. Automatic Measurement of Kidney and Liver Volumes from MR Images of Patients Affected by Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 30(8):1514-1522, 2019 08.
25. Gregory AV, Anaam DA, Vercnocke AJ, et al. Semantic Instance Segmentation of Kidney Cysts in MR Images: A Fully Automated 3D Approach Developed Through Active Learning. J Digit Imaging. 34(4):773-787, 2021 08.
26. Taylor J, Thomas R, Metherall P, et al. An Artificial Intelligence Generated Automated Algorithm to Measure Total Kidney Volume in ADPKD. KI Rep. 9(2):249-256, 2024 Feb.
27. Sore R, Cathier P, Vlachomitrou AS, et al. Deep learning-based segmentation of kidneys and renal cysts on T2-weighted MRI from patients with autosomal dominant polycystic kidney disease. Eur Radiol Exp. 8(1):122, 2024 Oct 30.
28. Iijima H, Tada T, Hashimoto M, et al. Utility of ultrasonography for predicting indications for tolvaptan in patients with autosomal dominant polycystic kidney disease. J Med Ultrason (2001). 50(1):81-87, 2023 Jan.
29. Xie Y, Xu M, Chen Y, Zhu X, Ju S, Li Y. The predictive value of renal parenchymal information for renal function impairment in patients with ADPKD: a multicenter prospective study. Abdom Radiol. 47(8):2845-2857, 2022 08.
30. Sise C, Kusaka M, Wetzel LH, et al. Volumetric determination of progression in autosomal dominant polycystic kidney disease by computed tomography. Kidney Int. 2000 Dec;58(6):2492-501.
31. Hammoud S, Tissier AM, Elie C, et al. Ultrasonographic renal volume measurements in early autosomal dominant polycystic disease: comparison with CT-scan renal volume calculations. Diagn Interv Imaging. 96(1):65-71, 2015 Jan.
32. Moriyama T, Nakayama Y, Soejima M, et al. Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations. Clin Exp Nephrol. 25(3):251-260, 2021 Mar.
33. O'Neill WC, Robbin ML, Bae KT, et al. Sonographic assessment of the severity and progression of autosomal dominant polycystic kidney disease: the Consortium of Renal Imaging Studies in Polycystic Kidney Disease (CRISP). Am J Kidney Dis. 2005 Dec;46(6):1058-64.
34. Jagtap JM, Gregory AV, Homes HL, et al. Automated measurement of total kidney volume from 3D ultrasound images of patients affected by polycystic kidney disease and comparison to MR measurements. Abdom Radiol. 47(7):2408-2419, 2022 07.
35. Balbo BE, Sapienza MT, Ono CR, et al. Cyst infection in hospital-admitted autosomal dominant polycystic kidney disease patients is predominantly multifocal and associated with kidney and liver volume. Braz J Med Biol Res. 47(7):584-93, 2014 Jul.
36. Bobot M, Ghez C, Gondouin B, et al. Diagnostic performance of [(18)F]fluorodeoxyglucose positron emission tomography-computed tomography in cyst infection in patients with autosomal dominant polycystic kidney disease. Clin Microbiol Infect. 22(1):71-77, 2016 Jan.
37. Suwabe T. Cyst infection in autosomal dominant polycystic kidney disease: our experience at Toranomon Hospital and future issues. [Review]. Clin Exp Nephrol. 24(9):748-761, 2020 Sep.
38. Suwabe T, Ubara Y, Ueno T, et al. Intracystic magnetic resonance imaging in patients with autosomal dominant polycystic kidney disease: features of severe cyst infection in a case-control study. BMC Nephrol. 17(1):170, 2016 11 09.
39. Riyahi S, Dev H, Blumenfeld JD, et al. Hemorrhagic Cysts and Other MR Biomarkers for Predicting Renal Dysfunction Progression in Autosomal Dominant Polycystic Kidney Disease. J Magn Reson Imaging. 53(2):564-576, 2021 02.
40. Schumacher K, Prince MR, Blumenfeld JD, et al. Quantitative susceptibility mapping for detection of kidney stones, hemorrhage differentiation, and cyst classification in ADPKD. Abdom Radiol. 49(7):2285-2295, 2024 Jul.
41. Neuville M, Hustinx R, Jacques J, Krzesinski JM, Jouret F. Diagnostic Algorithm in the Management of Acute Febrile Abdomen in Patients with Autosomal Dominant Polycystic Kidney Disease. PLoS ONE. 11(8):e0161277, 2016.
42. Oh J, Shin CI, Kim SY. Infected cyst in patients with autosomal dominant polycystic kidney disease: Analysis of computed tomographic and ultrasonographic imaging features. PLoS ONE. 13(12):e0207880, 2018.
43. Mei CL, Xue C, Yu SQ, et al. Executive Summary: Clinical Practice Guideline for Autosomal Dominant Polycystic Kidney Disease in China. Kidney Dis. 6(3):144-149, 2020 May.
44. Kwon HW, Lee HY, Hwang YH, Park HC, Ahn C, Kang KW. Diagnostic performance of 18F-FDG-labeled white blood cell PET/CT for cyst infection in patients with autosomal dominant polycystic kidney disease: a prospective study. Nucl Med Commun. 37(5):493-8, 2016 May.
45. Pijl JP, Glaudemans AWJM, Slart RHJA, Kwee TC. 18F-FDG PET/CT in Autosomal Dominant Polycystic Kidney Disease Patients with Suspected Cyst Infection. J Nucl Med. 59(11):1734-1741, 2018 11.
46. Neuville MF, Lovinfosse P, Jadoul A, et al. The use of a visual 4-point scoring scale improves the yield of 18F-FDG PET-CT imaging in the diagnosis of renal and hepatic cyst infection in patients with autosomal dominant polycystic kidney disease. Eur J Nucl Med Mol Imaging. 48(1):254-259, 2021 01.
47. Weinreb JC, Rodby RA, Yee J, et al. Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Radiology. 298(1):28-35, 2021 01.
48. Davenport MS, Perazella MA, Yee J, et al. Use of Intravenous Iodinated Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Radiology. 294(3):660-668, 2020 Mar.
Disclaimer
The ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient’s clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those examinations generally used for evaluation of the patient’s condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the FDA have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.